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Summary
 
In systemic autoimmune disease, self-tolerance fails, leading to autoantibody production. A
central issue in immunology is to understand the origins of activated self-reactive B cells. We
have used immunoglobulin (Ig) transgenic mice to investigate the regulation of autoreactive B
cells with specificity for self-IgG2a (the rheumatoid factor [RF] specificity) to understand how
normal mice regulate RF autoantibodies and how this fails in autoimmune mice. We previ-
ously showed that normal mice do not tolerize the AM14 RF clone, nor do they appear to ac-
tivate it. Here we show that in Fas-deficient autoimmune mice, the picture is quite different.
RF B cells are activated to divide and secrete, but only when the autoantigen is present. Thus,
B cells that are ignored rather than anergized in normal mice can be stimulated to produce au-
toantibody in Fas-deficient mice. This demonstrates a novel developmental step at which intact
Fas–Fas ligand signaling is required to regulate B cells in order to prevent autoimmunity. These
data also establish the relevance of ignorant self-specific B cells to autoantibody production in
disease and prove that in the case of the RF specificity, the nominal autoantigen IgG2a is the
driving autoantigen in vivo.
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A
 
characteristic of systemic autoimmune diseases is the
production of high-titer autoantibodies (autoAbs)
 
1
 
 to
a variety of self-constituents (1). These autoAbs are impor-
tant diagnostic markers of disease, and their patterns are
specific for particular autoimmune diseases (1). They are
also important because autoAbs can be pathogenic under
certain circumstances (2–4). The pathogenic consequences
of activated autoreactive B cells are not limited to autoAb
production, as B cells also promote T cell activation (5).
Thus, it has been of great interest to understand the ori-
gins of autoreactive B cells in autoimmune animals and,
conversely, how they are controlled in normal animals. It is
possible that intrinsic B cell defects (6–8) leading to B cell
hyperactivity (9, 10) account for the production of auto-
Abs. In this view, autoAbs are the result of nonspecific B
cell activation. On the other hand, an early clue to an im-
portant role of autoantigen (autoAg) in the genesis of such
B cells in autoimmune animals came from the study of
autoAb hybridomas. These were found to be somatically
mutated and clonally related (11–19). In many cases, the
somatic mutations had high ratios of replacement to silent
mutations in the CDRs, and in some instances, mutations
led to higher affinity for the nominal autoAg. These data
were interpreted as evidence that autoAg played a critical
role in driving the expansion and selection of autoreactive
B cells. These interpretations were only indirect; the analy-
sis of autoAb hybridomas could not provide direct proof
that autoAg drives autoreactive B cells, and this issue re-
mains controversial (20).
A second issue is at what stage tolerance must fail in or-
der to allow for the developmental progression of self-reac-
tive B cells. Transgenic (Tgic) mice have been invaluable
tools in efforts to address this question. The earliest models,
using model antigens such as hen egg lysozyme (HEL) or
class I, revealed deletion, receptor editing, and anergy as
basic mechanisms of B cell self-tolerance (21–24). When
the anti-HEL or anti–class I models were crossed onto the
Fas-deficient background, tolerance was generally found to
be intact (25, 26). Studies of model autoAgs do not permit
a clear extrapolation to the situation in disease. This is be-
cause particular autoAgs, such as DNA, chromatin, or self-
IgG are targets in autoimmune diseases (1); tolerance to
many other autoAgs remains intact even in systemic au-
toimmune disease. Why these autoAgs are preferred targets
is still unclear. Nonetheless, the regulation of autoreactive
B cells with disease-related specificities must be unique and
could not be readily predicted by the behavior of B cells
specific for model autoAgs that are not actual disease targets.
Recognizing this, several groups have extensively stud-
ied Tgic mice expressing anti–single-stranded (ss)DNA
 
1
 
Abbreviations used in this paper:
 
 AFCs, antibody-forming cells; ds, double-
stranded; ELISpot, enzyme-linked immunospot assay; GC, germinal cen-
ter; HEL, hen egg lysozyme; N, nontransgenic; RF, rheumatoid factor;
ss, single-stranded; Tg, transgene; Tgic, transgenic. 
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and/or –double-stranded (ds)DNA (27–38). Such B cells
may be regulated by receptor editing, deletion, and anergy,
possibly depending on the fine specificity of the cell. In
contrast to the artificial autoAg systems, anti-DNA B cells
that use a 3H9 H chain transgene (Tg) are activated in Tgic
mice on the MRL.Fas
 
lpr
 
 background (39). This is an ex-
tremely important observation because it demonstrates that
in an autoimmune mouse, B cells with disease-related spec-
ificities may indeed be regulated differently from B cells
specific for arbitrary “self” antigens. However, it is not yet
clear how these activated DNA-specific B cells arise,
whether by defeating central tolerance, anergy, or both.
The regulation of rheumatoid factors (RFs), another typ-
ical yet less-studied autoAb, may again be different. Our
group has investigated a model based on an RF, AM14,
that was originally isolated from an MRL.Fas
 
lpr
 
 mouse (40).
Because AM14 binds only to IgG2a of the “a” allotype
(IgG2a
 
a
 
), we have the opportunity to study the Tgic B cells
in the presence and absence of autoAg in both normal and
autoimmune-prone backgrounds. This capability is similar
to the design of the model autoAg systems but is not possi-
ble in other Tgics expressing authentic autoAbs. We have
previously shown that AM14 B cells are clonally ignorant.
They are not tolerized by deletion, editing, or anergy in
normal BALB/c mice, nor do they appear activated in the
absence of intentional immunization (41).
We suggested based on these results that the precursors
of autoAb-secreting cells were not necessarily tolerized in
normal animals and became selectively activated in autoim-
mune animals due to increased propensity to activate the
otherwise quiescent cells and/or a failure to downregulate
them once activated. This hypothesis, inferred from the
phenotype of normal animals, has never been tested in au-
toimmune mice. It remained possible that such cells would
also be ignored in the autoimmune-prone animal. Alterna-
tively, RF B cells might be activated in the autoimmune-
prone background regardless of whether autoAg is present.
To investigate these possibilities, we crossed the separate
H and L chain Tgs that comprise the AM14 RF specificity
onto both the C57B6.MRL.Fas
 
lpr
 
 (B6/lpr: IgH
 
b
 
, Ag
 
2
 
) and
B6/lpr/IgH
 
a
 
 background. B6/lpr mice produce large num-
bers of autoAbs, including RF and antichromatin and have
a mild autoimmune disease (7, 42–44), owing chiefly to
their Fas deficiency but also to some B6-derived back-
ground genes (45). The B6/lpr strain was a particularly at-
tractive model, as congenic strains were available that both
had B6/lpr/IgH
 
a 
 
and lacked the autoAg (7). We studied the
activation state of RF B cells and T cells in vivo in age-
matched sets of congenic mice. These studies have pro-
vided insights into the role of autoAg in driving B cell au-
toimmunity, the identity of the RF Ag, where tolerance
breaks down to permit autoAb production, and the role of
Fas in this process.
 
Materials and Methods
 
Mice.
 
The following three strains of mice were constructed
from our BALB/c-based Tgic lines: AM14Vh/B6/lpr (H chain
 
Tgics), AM14V
 
k
 
/B6lpr, and AM14V
 
k
 
/B6/lpr/IgH
 
a
 
 (L chain
Tgics). These were derived by continuous backcrossing to either
B6/lpr (originally obtained from The Jackson Laboratory) or B6/
lpr/IgH
 
a
 
 mice (7) (a gift of Dr. Robert Eisenberg, University of
Pennsylvania, Philadelphia, PA). B6/lpr and B6/lpr/IgH
 
a
 
 mice
were also maintained by intercrossing at Yale University. At each
generation, Tgic mice were identified by PCR (see below) for
breeding to the next generation. At BC1, mice were typed for
homozygosity for the Fas
 
lpr
 
 mutation by PCR (5), which was
confirmed at BC2. The IgH
 
a
 
 genotype was also confirmed at
BC1 by an allele-specific PCR assay for IgG2a
 
a
 
 versus IgG2a
 
b
 
.
From BC4 (97% B6 genes) and beyond, AM14Vh/B6/lpr mice
were crossed with AM14Vl/B6/lpr mice to create Ag
 
2
 
 double-
Tgic controls (HL
 
b
 
 mice) or to AM14Vh/B6/lpr/IgH
 
a
 
 mice to
create Ag
 
1
 
 double-Tgic experimental mice (HL
 
ab
 
). All other
transgenotypes (H, H chain only; L, L chain only; and N, non-
Tgic) were also obtained in these crosses and were analyzed as ad-
ditional controls (see Results). Age-matched IgH
 
b
 
 or IgH
 
ab
 
 mice
(40) that were wild type at the Fas locus were available on the
BALB/c background and were analyzed as controls. All mice
were housed in the same room in our specific pathogen–free bar-
rier colony.
 
PCR Genotyping.
 
PCR to genotype for H and L Tgs, IgH
genotype, and the lpr mutation was performed as described (40).
PCR to genotype the IgG2a locus was performed as previously
described (46).
 
Antibodies.
 
The selection, preparation, and labeling of anti-
bodies was as described (40, 41). Anti-CD3–biotin was obtained
from PharMingen.
 
Cell Isolation and FACS™ Analysis.
 
These were performed
essentially as described (41) with the following modifications.
Spleens were harvested, weighed, and then divided, with a por-
tion being quick-frozen in OCT for later immunohistochemical
analysis. The other portion was weighed again and then pro-
cessed into a single-cell suspension. Red cells were then lysed
with ammonium chloride/Tris solution. Cell number was deter-
mined by counting in a hemocytometer, and a corrected total
number of cells in the spleen was derived by considering the frac-
tion by weight of the total spleen that was used to create the cell
suspension. In most experiments, cells were preincubated with
saturating concentrations of 2.4G2 (rat anti–mouse FcR) to block
nonspecific binding. Stained cells were analyzed on a FACSCali-
bur™ (Becton Dickinson Immunocytometry Systems). When
possible, live gating using propidium iodide was used to exclude
dead cells. When four labeled mAbs were used, forward and side
scatter profiles were used to exclude most dead cells and RBCs.
At least 30,000 events were collected for two- and three-color
analysis, and 50,000 events were collected for four-color analysis.
 
ELISA and Enzyme-linked Immunospot Assay.
 
The assays were
performed as described (41).
 
Statistics.
 
Data were not distributed normally, mandating the
use of Mann-Whitney nonparametric tests (two-tailed) to com-
pare groups. Tests were performed using StatView 4.5 (Abacus
Concepts, Inc.).
 
Results
 
Protocol.
 
Age-matched cohorts of AM14 Tgic mice
were established on the B6/lpr (IgH
 
b
 
) and B6/lpr/IgH
 
a
 
backgrounds. As these were generated by intercrossing H
and L single-Tgic mice, all possible genotypes were cre-
ated, among which H, HL, and N were extensively stud- 
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ied. In addition, similar age-matched cohorts were gener-
ated on the BALB/c (IgH
 
a
 
) and congenic CB.17 (IgH
 
b
 
)
backgrounds. These strains were available as nonautoim-
mune, Fas-sufficient controls. Mice were allowed to age to
4–7 mo to allow spontaneous autoimmunity to develop, at
which point they were killed and analyzed as described
below.
 
Spleen Cell Number.
 
The number of total splenocytes
was greater in the HL
 
ab
 
 Tgics (which had the AM14 au-
toAg) compared with the corresponding HL
 
b
 
 Tgic mice,
which lacked the autoAg (Table I;
 
 P 
 
5 
 
0.0003). Interest-
ingly, a similar difference was observed in the H chain Tgic
mice (
 
P
 
 
 
5 
 
0.0017). This was not due to differences be-
tween B6/lpr and B6/lpr/IgH
 
a
 
 per se, as no such difference
was seen in the N controls (Table I;
 
 P 
 
5 
 
0.53). Notably,
this difference was also not observed in the comparison be-
tween BALB/c and CB.17 HL Tgics of similar age (
 
P
 
 
 
5
 
0.76).
 
Number and Percentage of AM14 Id Cells.
 
Percentages (Fig.
1) and numbers (Table I) of AM14 Id
 
1
 
 B cells were greater
in the HL
 
ab
 
 Tgic mice compared with HL
 
b
 
 mice. Again, H
chain Tgic mice were similar in this regard. Indeed, many
H
 
ab
 
 mice had substantial percentages of Id
 
1
 
 B cells,
whereas this was only rarely observed among H
 
b
 
 mice.
Such cells are detectable only at low frequency in young
(reference 40) or old BALB/c or CB.17 H Tgics (not
shown). AM14 Id
 
1
 
 cells in H
 
ab
 
 Tgics presumably represent
cells with endogenous V
 
k
 
8 L chains that are identical to or
resemble the germline-encoded Tgic V
 
k
 
8. This interpreta-
tion is supported by the fact that among LPS hybridomas
isolated from BALB/c H chain Tgics, both of the Id
 
1
 
 cell
lines that were isolated had the same endogenously derived
V
 
k
 
8 sequence as the Tg L chain (Shlomchik, M., unpub-
lished data). If indeed these Id
 
1
 
 cells in H-only mice re-
constitute the RF specificity of the original AM14 HL pair,
finding higher percentages in the H
 
ab
 
 mice compared with
the H
 
b
 
 mice would be consistent with an active, autoAg-
driven process in which rare RF B cells are substantially ex-
panded. RF ELISpot data (see below) is also consistent
with this interpretation; however, confirmation of it will
 
Table I.
 
Summary of Total and RF Id
 
1
 
 B Cells in Spleen
 
Transgene
type
 
*
 
IgH allotype
 
‡
 
Fas genotype Total cells
 
§
 
P
 
 value
 
i
 
Idiotype-positive
 
¶
 
 
cells
 
P
 
 value
 
i
 
3
 
10
 
2
 
7
 
3
 
10
 
2
 
5
 
HL ab
 
lpr/lpr
 
6.2 
 
6
 
 0.17
0.0003
43.3 
 
6
 
 1.20
0.0016
HL bb
 
lpr/lpr
 
2.8 
 
6
 
 0.08 12.8 
 
6
 
 0.39
Ha b
 
lpr/lpr
 
8.8 
 
6
 
 0.28
0.0017
43.1 
 
6
 
 3.15
0.0076
Hb b
 
lpr/lpr
 
4.1 
 
6
 
 0.16 6.4 
 
6
 
 0.38
Na b
 
lpr/lpr
 
10.4 
 
6
 
 0.38
0.53
ND
ND
Nb b
 
lpr/lpr
 
12.9 
 
6
 
 0.48 ND
HL ab
 
1
 
/
 
1
 
5.4 
 
6
 
 0.15
0.76
164.2 
 
6
 
 5.10
0.70
HL bb
 
1
 
/
 
1
 
5.5 
 
6
 
 0.23 157.0 
 
6
 
 5.91
 
*
 
HL, heavy and light double-Tgic; H, heavy chain–only Tgic; N, non-Tgic.
 
‡
 
ab, heterozygous for IgH
 
a
 
 and IgH
 
b
 
; bb, homozygous for IgH
 
b
 
.
 
§
 
Mean 
 
6
 
 SEM.
 
i
 
Determined by Mann-Whitney test.
 
¶
 
Determined by multiplying the total cell number of individual mice by the percentage of Id
 
1
 
 cells indicated by FACS™ analysis.
Figure 1. Increased numbers of RF Id1 cells in
spleens of Tgic mice with AutoAg. The y-axis
shows on a logarithmic scale the calculated num-
bers of Id1 cells based on total cell counts and the
percentage of Id1 cells determined by FACS™
analysis. Each diamond is an individual mouse, and
the horizontal bar is the median. Mouse genotypes
are shown on the category axis as follows: HL, both
heavy and light Tgs; H, heavy Tg only; ab, het-
erozygous for IgHa and IgHb allotypes (i.e., autoAg
present); bb, homozygous for the IgHb allotype
(autoAg absent). Left panel, B6/lpr-derived strains;
right panel, BALB/c-derived strains. P values for
comparisons between each autoAg-positive versus
-negative group are shown above the graphs. The
numbers of mice analyzed are: 41 HLab, 31 HLb, 17
Hab, 17 Hb, 23 BALB/c HLab, and 19 CB.17 HLb.642 Autoantigen-specific Activation of RF B Cells
require isolation of the cells from Hab mice and sequencing
of their L chains.
Activation of AM14 Id Cells. Larger numbers of AM14
Id1 cells in mice that express the autoAg (i.e., when AM14
is an autoAb) suggests that spontaneous activation may be
occurring in this setting. This is indeed the case, as demon-
strated by expression of CD44 (47, 48) and by the presence
of Id1 ELISpots, which reflect differentiation into plasma
cells. Fig. 2 shows CD44 expression in AM14 HL and H
Tgics of both IgHa and IgHb allotypes. Many of the IgHa
mice had a substantial fraction of CD44hi/Id1 cells, a phe-
notype only rarely observed in IgHb mice. These data are
summarized over the entire cohort in Fig. 2 B as the ratio
of CD44hi/CD44lo Id1 cells. There is a statistically signifi-
cant difference in this measure between the IgHa and IgHb
mice of both HL (P 5 0.0009) and H (P 5 0.0007) geno-
types. A similar comparison of IgHa and IgHb mice on the
BALB/c background did not reveal any differences, sug-
gesting that accumulation of spontaneously activated RF B
cells is dependent on Fas deficiency.
Another measure of activation is differentiation into high
rate Ab-secreting cells, which we measured by ELISpot.
Similar to the CD44 data, a substantial proportion of both
HLab and Hab mice had high numbers of Id1 ELISpots (Fig.
3). The median difference between IgHa and IgHb mice
was 16-fold for HL Tgics (P , 0.0001) and 407-fold for H
Tgics (P 5 0.002). Again, there were no significant differ-
ences between BALB/c and CB.17 mice. To directly dem-
onstrate this, on a subset of H chain mice, we measured
RF ELISpots in both IgHa and IgHb B6/lpr mice. RF spots
were much higher in most Hab than in Hb mice (P  5
0.009). These findings directly demonstrate that in Ha
mice, concurrent with the expansion and differentiation of
Id1 cells, RF B cells are also expanded. In combination
with our other observations, this suggests that most of the
Id1 B cells are RF B cells as well.
Splenic Architecture. To confirm the identification of
AM14 Id1 B cells and antibody-forming cells (AFCs) by
FACS™ and ELISpot and to identify their locations in
vivo, frozen sections of spleens from representative Fas-
deficient animals (HL or H) were prepared and stained for
CD3 and Id expression (Fig. 4, A–D). Spleens from age-
matched HLab and HLb Fas-sufficient mice were similarly
prepared as controls (Fig. 4, E and F). Control mice of ei-
ther allotype had normal splenic architecture, with most
AM14 Id1 cells in B cell follicles and few AFCs in the red
pulp. In contrast, large numbers of cells staining darkly
with the 4-44 anti-Id were detected in Fas-deficient IgHa
mice of both HL and H genotypes (Fig. 4, A and C). Such
cells were prominent in the red pulp, a site known to har-
bor plasma cells early after immunization in normal mice
(49). These putative AFCs were more prominent in mice
that also had large numbers of ELISpots (data not shown).
In addition, such cells were also seen at the border of the T
and B cell zones. In contrast to IgHa HL and H mice,
darkly staining cells were rare to absent in all IgHb mice ex-
Figure 2. Increased fraction of CD44hi Id1 B cells in spleens of Tgic
mice with autoAg. (A) Representative FACS™ data from typical mice
from a single experiment. Staining with anti–Id 4-44 is shown on the
y-axis and anti-CD44 is on the x-axis. 4% contour plots are depicted. The
percentage of total lymphocytes in the upper quadrants is shown. Left
panels show HL1/1 mice that are wild-type at Fas (BALB/c-derived
strains). Center and right panels are from B6/lpr-derived strains, with the
center panels from HL Tgics and the right from H Tgics. As indicated, the
top row is from mice that ex-
press the autoAg (IgHab), and the
bottom row is from mice that
lack the autoAg (IgHb). (B)
Summary of FACS™ data as
represented in A for all analyzed
mice. The y-axis shows on a log-
arithmic scale the ratio of
CD44hi (top right quadrant in A)
to CD44lo (top left quadrant in
A). Each diamond is an individ-
ual mouse, and the horizontal
bar is the mean. The layout of
the figure is otherwise as in Fig.
1. The numbers of mice ana-
lyzed are: 38 HLab, 29 HLb, 17
Hab, 16 Hb, 22 BALB/c HLab,
and 19 CB.17 HLb.643 Wang and Shlomchik
amined. In mice of both allotypes, cells staining moderately
for the AM14 Id were seen scattered within the T cell
zones, a site where B cells are rarely observed in normal
mice (Fig. 4, E and F). Others who have examined the
splenic architecture of Fas-deficient mice have also noted
the presence of B cells scattered in the T zones (50, 51).
Our data suggest that such localization is not necessarily de-
pendent on B cell receptor engagement, as it was equally
seen in the presence or absence of Ag. Finally, residual B
cell zones, located at the edges of the T zones, containing
lightly staining Id1 cells were noted in all IgHa mice. Some
IgHb mice virtually lacked these B zones (Fig. 4 B),
Figure 3. Increased numbers of Id1
ELISpots in spleens of Tgic mice with au-
toAg. The y-axis shows on a logarithmic
scale the calculated numbers of Id1
ELISpots based on total cell counts and the
number of Id1 ELISpots determined on a
measured number of cells as described in
Materials and Methods. The layout of the
figure is otherwise as in Fig. 1. The num-
bers of mice analyzed are: 38 HLab, 29 HLb,
16 Hab, 16 Hb, 22 BALB/c HLab, and 19
CB.17 HLb.
Figure 4. Histologic analysis
of spleens. Frozen sections of
spleens from representative mice
were stained with anti-CD3 (blue)
and 4-44 anti-Id (gold). A, C,
and E are from IgHab mice, and
B, D, and F are IgHb. A–D, B6/
lpr mice; E and F, BALB/c
background mice. A, B, E, and F
are HL mice, whereas C and D
show spleens from H-only Tgic
mice. T cell zones are indicated
by T; foci of darkly staining Id1
plasma cells are shown by ar-
rows. Asterisks indicate T–B cell
borders in which Id19 B cells are
mixing with adjacent T cells.
HLab (A) and Hab (C) are re-
markable for large numbers of
Id19 plasma cells as well as lighter-
staining Id19 cells, both of which
are absent in the IgHb congenics
(B and D). Fas-sufficient mice (E
and F) show normal histology,
with well-defined T and B zones
with most Id1 cells in the folli-
cles and few plasma cells. There
are no remarkable differences
between the allotype congenics
in E and F.644 Autoantigen-specific Activation of RF B Cells
whereas in others they appeared less well developed (not
shown). This immunohistological phenotype may underlie
the observation that overall, IgHb mice have fewer AM14
Id1 B cells as determined by FACS™.
T Cell Activation. B cells play a key role in the activa-
tion of T cells in MRL/lpr mice (5, 52). Many activated T
cells in Fas-deficient mice express the B220 antigen (53).
This is an activation marker in normal mice (54), and the
weight of data suggests that in Fas-deficient mice, B2201 T
cells represent accumulating cells that had been activated
and, in the presence of Fas, would have been eliminated af-
ter activation. Thus, the frequency of such T cells is a mea-
sure of the extent of T cell activation. In the course of our
analysis of the B6/lpr cohorts, we determined the percent-
ages of B2201 T cells as demonstrated in Fig. 5. The extent
of T cell activation, as measured by B2201 T cell percent-
ages, depends on whether the B cell autoAg is present. This
was true in both the HL and H Tgics, but the IgH geno-
type did not have an effect on B2201 T cell numbers in N
mice. Similar conclusions were reached based on B2201 T
cell numbers (data not shown), which is not surprising be-
cause HLab mice also have greater numbers of splenocytes
than HLb mice (Table I).
Discussion
The origin of autoreactive B cells has been a question of
great interest: are these cells that aberrantly escape central
tolerance, are abnormally rescued from an anergic state, or
are derived from clonally ignorant B cells whose activation
or cell death is improperly regulated? Although several of
these pathways may operate—depending on the autoAg, B
cell affinity, and stage of disease—it is important to demon-
strate experimentally which pathways are possible and
thereby have appropriate models for further study. Here,
we show that RF B cells that are clonally ignorant in
BALB/c mice are no longer ignorant but rather are stimu-
lated in the presence of their autoAg in the B6/lpr genetic
background. We were able to demonstrate both increased
numbers of autoreactive B cells and differentiation of these
B cells into AFCs in mice that were genetically capable of
expressing the autoAg, compared with congenic mice that
lacked the autoAg.
The existence of low-affinity “natural” autoantibodies in
normal individuals has been known for a long time (55,
56). These B cells are likely to be clonally ignorant, as sug-
gested by the phenotype of AM14 B cells in normal mice.
What has remained controversial is whether such B cells
had any relevance or relationship to pathologic autoanti-
bodies produced in systemic autoimmune disease (56, 57).
Our results indicate that clonally ignorant cells can indeed
be relevant precursors for pathologic autoantibodies.
Evidence that Proliferation and Differentiation of Autoreactive
B Cells In Vivo Depends on AutoAg. A second issue that
our data addresses is the role of autoAg-stimulated versus
nonspecific B cell activation in the induction of autoAbs.
Several studies had shown that antibodies to a wide variety
of antigens can be detected in autoimmune animals, sug-
gesting that polyclonal activation was at work (58–60). On
the other hand, the oligoclonal nature of B cell hybridomas
specific for IgG, DNA, nucleosomes, or Sm isolated from
autoimmune animals suggested an antigen-driven process
(11, 13–19). Notably, a nonrandom pattern of somatic mu-
tations and the presence of certain mutations that increased
the affinity for Ag suggested that Ag was playing a role in
driving at least some autoimmune responses. These con-
flicting interpretations were based on indirect inferences.
Moreover, neither argument could establish whether au-
toAg was required or was simply altering or exacerbating
an underlying polyclonal process.
The data in this report provide more direct evidence that
autoAg is required for the activation of autoreactive B cells.
In the presence of autoAg, substantial accumulations of RF
plasma cells were observed in the spleens of Tgic mice
compared with those mice that lacked the autoAg. Re-
markably, only in the presence of the autoAg did H chain
Tgic mice efficiently select rare endogenous L chains that
reconstruct both the idiotype and RF specificity of the
original HL pair that comprised AM14. This phenomenon
provides an additional strong argument for the role of au-
toAg in driving RF B cells.
These conclusions are based on direct ELISpot data and
splenic histology; we did not systematically measure and do
not present serum RF data that are at best an indirect mea-
surement of B cell activation and differentiation. Serum
RF data are widely gathered in humans, where such direct
measurements as ELISpot are not feasible. In our system,
serum RF levels would be influenced by Ag competition
and increased clearance rates of immune complexes as well
as by competition by IgG2a naturally occurring in serum.
These confounding features would be present in IgHa mice
but not in IgHb mice, precluding any meaningful compari-
son. Furthermore, it would be difficult in such assays to
Figure 5. Increased percentage of B2201 T cells in spleens of Tgic
mice with the autoAg. B2201 T cells were identified by FACS™ analysis
as described in Materials and Methods. The y-axis shows percentages
from individual mice. Each diamond is an individual mouse, and the hor-
izontal bar is the mean. The layout of the figure is otherwise as in Fig. 1.
Only B6/lpr mice are shown in this figure, as the percentages in the
BALB/c-derived strains were negligible. The numbers of mice analyzed
are: 39 HLab, 29 HLb, 18 Hab, 17 Hb, 18 Nab, and 19 Nb.645 Wang and Shlomchik
distinguish RF secreted by B cells expressing endogenous
Ig genes. ELISpot and histology assays are not subject to
these concerns.
The Nominal AutoAg IgG2a Is the In Vivo Antigen Driving
RF B Cells. These observations raise the related issue of
the identification of the true autoAg. It has been contro-
versial whether the nominal Ags assayed in vitro as targets
of autoAbs are actually those that drive autoreactive B cell
clones in vivo (61, 62). Perhaps the strongest evidence in
favor of nominal Ags as actual Ags came from a single study
in which the clonality and specificity were simultaneously
determined for a large number of hybridomas isolated from
a single autoimmune mouse (63). Nearly all of the ex-
panded clones could be assigned to one of a relative few
nominal autoAb specificities, again suggesting that the
nominal antigens were driving most of the clonal expan-
sion. As congenic strains were compared in this study, the
only important difference between the two strains is almost
certainly the IgH locus allotype and, in particular, the pres-
ence or absence of IgG2aa, which is the only ligand for
AM14 that is encoded by the IgH locus (Shlomchik, M.,
unpublished data). Thus, IgG2aa is sufficient in vivo to
drive B cell clonal expansion and to recapitulate the origi-
nal expansion that must have occurred in the MRL/lpr
mouse from which AM14 was isolated as a hybridoma. No
other autoAg on the B6/lpr (IgHb) background was capa-
ble of driving this activation.
T Cell Activation Is Promoted by the RF B Cell Antigen.
A surprising observation was that T cell activation, as re-
flected by the accumulation of B2201 T cells, was affected
by the presence of the B cell Ag. This means that the ex-
tent of B cell activation of one particular clone was suffi-
cient to affect the activation of polyclonal T cells. The
mechanism for this is unclear but intriguing. It could be an
indirect effect due to cytokines produced by B cells (64–
67). More likely, it is a direct effect of T–B cell collabora-
tion. Recently, our group has shown that the absence of B
cells affects T cell activation (5). Sobel and colleagues also
showed in mixed BM chimeras that Fas-deficient B cells
are largely responsible for promoting T cell activation (52)
and that cognate interactions are required for autoAb elici-
tation (68). Our recent data (69) demonstrate that this ef-
fect on T cell activation is independent of secreted anti-
body, again arguing for a direct, cognate interaction. To
explain the effect of the B cell Ag on T cell activation we
observed here, one would have to suppose that AM14 B
cells could activate a substantial enough fraction of T cells
to make this pathway apparent by bulk FACS™ analysis. It
is unlikely that there is a high frequency of T cells specific
for self-IgG2a, the AM14 antigen. However, RF B cells
can take up immune complexes and present a wide variety
of autoAgs, provided they were complexed with self-IgG
(70). This is expected to be the case in B6/lpr mice, which
produce a variety of IgG2a autoAbs, including antichroma-
tin (68). Indeed, this feature of RF B cells—the ability to
present many autoAgs to T cells and thus garner T cell
help—may explain why RF is a predominant specificity in
Fas-deficient mice (63) as well as in several autoimmune
diseases. It is worth noting that although the origin of
B2201 T cells in lpr mice is unclear, most “double-nega-
tive” T cells arise from a CD81 T cell precursor (71, 72). If
the generation of B2201 T cells is related to the same pro-
cess, then an effect of B cells on CD81 T cells may be play-
ing a role. In this regard, activated and memory phenotype
CD81 T cells fail to accumulate in MRL/lpr mice in the
absence of B cells (5). Further work will be required to ex-
pand on this unexpected observation and to identify the T
cells promoted by RF B cells and the autoAgs that are rec-
ognized.
Implications for the Role of Fas/FasL in Regulating Autoim-
munity. Fas deficiency is the major determinant of autoAb
production in B6/lpr mice (44, 45). Because of constraints
and logistics of animal breeding as well as the desire to
compare results to those previously obtained on the
BALB/c background (40,41), we have only been able to
compare Fas-deficient mice on the B6 background to Fas-
sufficient mice on the BALB/c background. Thus, we can-
not formally rule out a role for background genes in the B6
strain. However, this seems very unlikely, as neither strain
background is associated with autoimmunity or RF pro-
duction and especially because many of the phenotypes we
show—high numbers of RF ELISpots, activated B cells at
the T–B interface and in the red pulp, and accumulation of
B2201 T cells—are distinctive to the Fas-deficient pheno-
type. With this caveat in mind, our results bear on how Fas
normally prevents autoAb production. Fas is expressed
throughout B cell ontogeny, including in developing B
cells, newly anergized B cells, newly activated B cells, ger-
minal center (GC) B cells, and plasma cells (73–79). In
principle, Fas deficiency could be critical at multiple stages
of B cell development and tolerance in promoting autoim-
munity. Our data demonstrate that Fas deficiency need not
act at early stages of tolerance (editing, deletion, and
anergy) to promote autoreactivity. In the presence of
functional Fas, AM14 B cells develop beyond these stages
and are quiescent in the presence or absence of antigen. Fas
must therefore play an important role in the regulation of
RF B cells during or after autoAg-specific activation, be-
cause when Fas is deficient, these B cells expand, persist,
and make autoAb, but only in the presence of autoAg. It is
also possible that Fas is acting more indirectly, e.g., by
causing increased IgG2a autoAg levels. In our case, this is
doubtful, as the average serum IgG2a level in a small group
of 4–5-mo-old HLab mice is 40 6 19 mg/ml (6 1 SD),
levels that are similar to those in BALB/c mice. More work
needs to be done to pinpoint at which stage(s) after the ini-
tial Ag activation event Fas is playing a role. It is notable in
this regard that although Fas is expressed in GC B cells, GC
reactions appear relatively normal in Fas-deficient mice
(80, 81). We observed that RF Tgic B6/lpr mice accumu-
lated large numbers of RF AFCs with few GCs (data not
shown) and had a relative B lymphopenia. This raises the
possibility that Fas on plasma cells is playing at least one
critical role.
Fas deficiency is likely not the cause of human systemic
autoimmunity. However, given the central role of Fas/646 Autoantigen-specific Activation of RF B Cells
FasL and possibly other homologues in the TNFR/TNF
family in immune system homeostasis, it does seem likely
that subtle defects in apoptotic pathways could underlie
human disease (82, 83). In this regard, pure Fas deficiency
may be an excellent model for understanding the in vivo
pathogenic mechanisms of such deficiencies. The overall
impact of this idea will only be known when genes that
promote lupus are identified (84, 85) and the Fas and Fas-
related signaling pathways are better elucidated.
AM14 B6/lpr Mice Have a Novel Phenotype Compared with
Other AutoAb Tgic Mice. Previous studies had investi-
gated how autoimmune-prone genetic backgrounds af-
fected the regulation of B cells that would normally be tol-
erant rather than ignorant. In the case of mice that edited
or deleted B cells specific for model self-antigens such as
Class I or HEL, it was generally found that regulation was
intact even in autoimmune-prone backgrounds (25, 26).
These data suggested that Fas and Fas/MRL defects did not
grossly impair central tolerance at this level for these auto-
Ags.
Regulation of B cells specific for either HEL or DNA
that are anergic in normal mice has also been investigated
on the B6/lpr or MRL/lpr backgrounds. In the case of
HEL, induction of anergy was essentially intact (25). In re-
lated experiments, Rathmell et al. transferred anergic anti-
HEL B cells along with activated CD41 T cells and dem-
onstrated that anergic cells are sensitive to elimination; this
did not occur when the T cells were deficient in FasL, in-
dicating a role for this pathway in the elimination of aner-
gic cells when T cell help was also being delivered (86). This
remains a potential pathway by which autoreactive B cells
could escape regulation, although unmanipulated Fas- or
FasL-deficient mice did not show gross defects in self-toler-
ance, as discussed above. The situation is different in our
model, as the B cells are not anergic and should be capable of
rescue by surface Ig cross-linking (87); thus, the Fas pathway
must function during additional regulatory steps (see below).
The situation is more complex for anti-DNA B cells;
their fate may depend on the specificity/affinity of the
DNA-specific B cell. In normal mice, anti-ssDNA B cells
appear anergic, albeit with a somewhat different phenotype
from the anti-HEL anergic B cells (27, 33). Some dsDNA-
specific B cells may be subject to receptor editing/deletion
(28–30, 88), but others may persist in the periphery local-
ized at the T–B interface, where they turn over rapidly (32,
34). In autoimmune MRL/lpr mice Tgic for the 3H9 H
chain, which can generate a variety of anti-DNA depend-
ing on the endogenous L chain (89), anti-DNA is seen in
the serum and hybridomas secreting antinuclear Abs with
homogenous nuclear staining are readily detected (31, 39).
These autoAbs may arise through several pathways; they
may result from loss of central tolerance, though recent de-
tection of anti-dsDNA B cells in BALB/c spleen by Roark
et al. (34) suggests that rescue from anergy may also be pos-
sible. Recent work by Weigert and colleagues on anti-
ssDNA site-directed Tgic mice also suggests that rescue
from anergy in MRL/lpr mice can occur (90). As there
cannot be an antigen-free anti-DNA Tgic, determination
of the ontogeny of the autoreactive B cells and, in particu-
lar, proving that this is a specific process is less straightfor-
ward than in the RF system. In any case, the anti-DNA
models represent a different scenario from ours in that the
precursors of anti-DNA Abs are thought to escape from ei-
ther deletion or anergy, whereas in the case of AM14, ig-
norant B cells are being positively selected by Ag.
Conclusion. We have shown that B cells that would be
ignored in a normal mouse are driven to activation, expan-
sion, and secretion in an autoimmune-prone Fas-deficient
mouse. This process is specific and requires the presence of
autoAg as well as the Fas defect. Because this is the only au-
toAb Tgic system, to our knowledge, that demonstrates
Ag-specific activation of defined, nontolerant mature B
cells, it provides a unique opportunity to study the tempo-
ral and spatial course of the initiating events of Fas-defi-
cient B cell autoimmunity and perhaps ultimately other
scenarios of B cell autoimmunity. It may also shed light on
the induction of autoreactive T cells and may be a system
for their generation and study in vitro and in vivo.
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